|
Ovarian cancer and bevacizumab: Real-world use across western countries and effect on survival in high-risk subgroups. |
|
|
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; MSD; Nykode Therapeutics |
Consulting or Advisory Role - Eisai (Inst); GlaxoSmithKline |
Research Funding - GlaxoSmithKline (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Regeneron (Inst) |
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Seagen (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca (Inst); GlaxoSmithKline (Inst); Nykode Therapeutics (Inst) |
|
|
Honoraria - AstraZeneca; GlaxoSmithKline; MSD; Roche |
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD; Roche |
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; MSD; Roche |
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); MSD (Inst); Tesaro (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst); MSD; MSD (Inst) |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Consulting or Advisory Role - OMICRON ApS |
|
|
Honoraria - Amgen; AstraZeneca; GlaxoSmithKline; MSD; Novartis; PharmaMar; Roche; Seagen |
Consulting or Advisory Role - Amgen; AstraZeneca; GlaxoSmithKline; MSD; Novartis; PharmaMar; Roche; Seagen |
Travel, Accommodations, Expenses - AstraZeneca; Roche |